Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Boehringer Ingelheim. (1/15/15). "Press Release: Boehringer Ingelheim and Sanofi Enter Into a Strategic Contract Manufacturing Alliance to Produce Biopharmaceuticals". Ingelheim.

Organisations Organisation Boehringer Ingelheim (Group)
  Organisation 2 Sanofi S.A. (EURONEXT: SAN, NYSE: SNY)
  Group Sanofi (Group) [since May 2011]
Products Product contract manufacturing (biologicals)
  Product 2 therapeutic antibody
Index term Index term Sanofi–Boehringer: biologics contract manufacturing, 201501– supply strategic manufacturing alliance to supply therapeutic ABs to Sanofi
Person Person Thoma, Heidrun (Boehringer 201109 Media + Public Relations)
     


Boehringer Ingelheim and Sanofi announced today that they enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies. Boehringer Ingelheim’s cell culture operations will provide contract manufacturing capacities to support the production of Sanofi’s biologics pipeline.

Under the terms of the agreement Sanofi will have access to Boehringer Ingelheim’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply. Initial product transfers will begin in early 2015.


About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 20 biopharmaceutical products to market. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its new brand Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one brand at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.

More information:
www.bioxcellence.com


Media contact

Heidrun Thoma
Boehringer Ingelheim

Media & PR
Heidrun Thoma
Binger Strasse 173
55216 Ingelheim am Rhein
GERMANY
Phone +49/6132/77 3966
Fax +49/6132/77 6601

   
Record changed: 2017-04-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top